Table 3. Effects of rs1053239 and rs2479 variation on changes of MS components levels in participants without antihypertensive, lipid-modulating, or hypoglycemic medication treatment during 5-year follow-up.

Dependent variable	Model 1					Model 2
	Adjusted R2	β a	P a	β b	P b	Adjusted R2	β c	P c	β d	P d
ΔWC (cm)	0.593	0.021	0.985	5.514	< 0.001	0.595	−1.059	0.296	5.493	< 0.001
ΔSBP (mmHg)	0.503	8.171	< 0.001	1.758	0.466	0.496	4.571	0.070	0.033	0.991
ΔDBP (mmHg)	0.356	3.708	0.001	−1.517	0.298	0.352	3.950	0.003	−1.017	0.469
ΔTG (mmol/L)	0.610	0.081	0.326	0.241	0.001	0.499	0.296	< 0.001	0.431	< 0.001
ΔHDL (mmol/L)	0.356	−0.021	0.752	−0.166	0.003	0.361	0.084	0.171	−0.176	0.002
ΔFPG (mmol/L)	0.201	0.104	0.610	0.130	0.576	0.201	0.117	0.609	0.140	0.533

Data were calculated from multivariate linear regression analysis. In Model 1, ^a β and ^a P for rs1053239 variation, and ^b β and ^b P for sex (female vs. male), with baseline level of corresponding dependent variable and changes in levels of other metabolic syndrome components adjusted. In Model 2, ^c β and ^c P for rs2479 variation, and ^d β and ^d P for sex (female vs. male), with baseline level of corresponding dependent variable and changes in levels of other metabolic syndrome components adjusted. Statistical significance (P < 0.05) is indicated in italics. Adjusted R² for adjusted coefficient of determination and β for partial regression coefficient.